UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 217

Sortiert nach

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells

Cell cycle (Georgetown, Tex.), 2015-02, Vol.14 (4), p.648-655

2015

Volltextzugriff (PDF)

EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate

Journal of controlled release, 2024-10, Vol.374, p.171-180

2024

Volltextzugriff (PDF)

Activating HER3 mutations in breast cancer

Oncotarget, 2018-06, Vol.9 (45), p.27773-27788

2018

Volltextzugriff (PDF)

Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers

Oncotarget, 2020-01, Vol.11 (1), p.31-45

2020

Volltextzugriff (PDF)

HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway

Genes & diseases, 2024-06, p.101354, Article 101354

2024

Volltextzugriff (PDF)

Understanding the biology of HER3 receptor as a therapeutic target in human cancer

Acta pharmaceutica Sinica. B, 2018-07, Vol.8 (4), p.503-510

2018

Volltextzugriff (PDF)

AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib

Biochemical pharmacology, 2022-10, Vol.204, p.115228-115228, Article 115228

2022

Volltextzugriff (PDF)

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review

European journal of pharmacology, 2024-08, Vol.977, p.176725, Article 176725

2024

Volltextzugriff (PDF)

Corosolic acid inhibits colorectal cancer cells growth as a novel HER2/HER3 heterodimerization inhibitor

British journal of pharmacology, 2021-03, Vol.178 (6), p.1475-1491

2021

Volltextzugriff (PDF)

Comparative evaluation of [sup.111]In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors

Oncology reports, 2015-08, p.1042

2015

Volltextzugriff (PDF)

Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody

Journal of pharmaceutical sciences, 2020-10, Vol.109 (10), p.3172-3180

2020

Volltextzugriff (PDF)

Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3

Peptides (New York, N.Y. : 1980), 2022-10, Vol.156, p.170858-170858, Article 170858

2022

Volltextzugriff (PDF)

Ultrasensitive electrochemical detection of cancer associated biomarker HER3 based on anti-HER3 biosensor

Talanta (Oxford), 2014-03, Vol.120, p.355-361

2014

Volltextzugriff (PDF)

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68 Ga-Labeled Tracers

International journal of molecular sciences, 2019, Vol.20 (5)

2019

Volltextzugriff (PDF)

Outcome and Human Epithelial Growth Factor Receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated using bromodeoxyuridine (BrdU) labelling

Breast cancer research : BCR, 2004-03, Vol.6 (3), p.R246-R246, Article R246

2004

Volltextzugriff (PDF)

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring

Future oncology (London, England), 2024-01

2024

Volltextzugriff (PDF)

Fabrication and investigation potential effect of lentinan and docetaxel nanofibers for synergistic treatment of breast cancer in vitro

Polymers for advanced technologies, 2022-05, Vol.33 (5), p.1468-1480

2022

Volltextzugriff (PDF)

Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers

Frontiers in molecular biosciences, 2022-02, Vol.9, p.847835

2022

Volltextzugriff (PDF)

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Frontiers in immunology, 2024, Vol.15, p.1376045-1376045

2024

Volltextzugriff (PDF)

A human epidermal growth factor receptor 3/heregulin interaction inhibitor aptamer discovered using SELEX

Biochemical and biophysical research communications, 2021-05, Vol.553, p.148-153

2021

Volltextzugriff (PDF)

Zebrafish her3 knockout impacts developmental and cancer-related gene signatures

Developmental biology, 2023-04, Vol.496, p.1-14

2023

Volltextzugriff (PDF)

Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways

International journal of biological macromolecules, 2023-09, Vol.248, p.125867-125867, Article 125867

2023

Volltextzugriff (PDF)

Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma

Pathology, 2023-08, Vol.55 (5), p.629-636

2023

Volltextzugriff (PDF)

A Janus-like DNA probekit for simultaneously imaging the homo- and heterodimerization of HER2 and HER3 on living tumor cells

Sensors and actuators. B, Chemical, 2022-01, Vol.350, p.130872, Article 130872

2022

Volltextzugriff (PDF)

The use of CrossMAb technology for the generation of bi- and multispecific antibodies

mAbs, 2016-08, Vol.8 (6), p.1010-1020

2016

Volltextzugriff (PDF)

1 – 25 von 217

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(183)
Mit Volltextzugriff
(193)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells

EV20/Omomyc: A novel dual MYC/HER3 targeting immunoconjugate

Activating HER3 mutations in breast cancer

Novel functional anti-HER3 monoclonal antibodies with potent anti-cancer effects on various human epithelial cancers

HER3: Unmasking a twist in the tale of a previously unsuccessful therapeutic pursuit targeting a key cancer survival pathway

Understanding the biology of HER3 receptor as a therapeutic target in human cancer

AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib

Mechanisms of acquired resistance to HER2-Positive breast cancer therapies induced by HER3: A comprehensive review

Corosolic acid inhibits colorectal cancer cells growth as a novel HER2/HER3 heterodimerization inhibitor

Comparative evaluation of [sup.111]In-labeled NOTA-conjugated affibody molecules for visualization of HER3 expression in malignant tumors

Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody

Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3

Ultrasensitive electrochemical detection of cancer associated biomarker HER3 based on anti-HER3 biosensor

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68 Ga-Labeled Tracers

Outcome and Human Epithelial Growth Factor Receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated using bromodeoxyuridine (BrdU) labelling

The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring

Fabrication and investigation potential effect of lentinan and docetaxel nanofibers for synergistic treatment of breast cancer in vitro

Antibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor Family in Cancers

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

A human epidermal growth factor receptor 3/heregulin interaction inhibitor aptamer discovered using SELEX

Zebrafish her3 knockout impacts developmental and cancer-related gene signatures

Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways

Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma

A Janus-like DNA probekit for simultaneously imaging the homo- and heterodimerization of HER2 and HER3 on living tumor cells

The use of CrossMAb technology for the generation of bi- and multispecific antibodies

Aktive Filter

Suchergebnisse filtern